Since the effective federal hemp-derived THC ban was approved in the latest budget deal, cannabis investors have taken the change as a sign the Trump administration is no longer serious about rescheduling.

This is probably wrong. Cannabis sector CEOs closer to the rescheduling process than most investors think the sector-changing reform is still on track.

The broad market and growth stocks started to have issues in late September and by early November everything went over the falls, cracking the intermediate-term trend of most indexes and stocks. Encouragingly, though, the market has rebounded this week as we march toward the Thanksgiving holiday--it’s good to see, but especially for growth measures, there’s still more proving to do. Of course, with a lot of cash, we’re willing to buy, and if we see strength continue into early next week (past the holiday period) we could start putting money back to work. For now, though, we think it’s best to be patient and see if the market (and, more important) growth stocks can tell us the selling storm is definitively over.

Note: Due to the Thanksgiving holiday, the Cabot Turnaround Letter weekly update won’t be published on Friday. Instead, the next update and the Catalyst Report will be sent out on December 5.

Given the obvious risks of the current macroeconomic environment (inflation, geopolitical volatility, etc.), it’s my contention that sector selectivity has never been more important. That is, when evaluating stocks for potential purchase, it’s imperative that we consider the potential impact the macro climate might have on said investment going forward.

I’m bullish for 2026. But I’m not confident about the next few weeks.

Last week’s much-anticipated earnings report from AI bellwether Nvidia (NVDA) and the overdue September jobs report were expected to provide answers to the recent angst. Both reports were great. Stocks plunged anyway. That’s a bearish sign.

The market is always unpredictable in the near term. But it seems the greater likelihood over the next several weeks is choppy at best, with a good chance of further downside. But things can change between now and the December issue, and new stocks could be highlighted in weekly updates or via trade alert.

In this issue, I highlight a covered call on a stock that has been flying high over the past month. It has enough momentum to make the call premium huge. It’s a good time to secure a high income on a stock that may have peaked in a market that looks dicey over the rest of the year.

Before we dive into this week’s covered call idea, we do need to clean up our CENX position from the November expiration cycle, as the call we sold expired worthless, leaving us with our stock, which we will sell for a net virtual breakeven. Here are the details:

The evidence has continued to worsen on balance, which has us remaining in a cautious stance. That said, we’re also flexible given some longer-term positives and a couple of near-term secondary readings that popped up last week, which have typically occurred near market low points. Given that the indexes aren’t horror shows, we’re still open to the action this month being a shorter-term shakeout —but with so many things having rolled over, the onus is on the market to prove itself on the upside. Right now, we favor staying close to shore; we’ll stick with our Market Monitor at a level 4.

This week’s list has something for everyone, with AI, fresh medical names, recent earnings winners and some turnarounds, too. Our Top Pick is a steadier name that’s strong partly due to the AI wave; the stock just gapped on earnings and delivered a solid outlook that should keep buyers interested. Aim to enter on weakness.

Happy Thanksgiving week, everyone! The market’s much-needed strong start to this holiday-shortened week is certainly something to be thankful for in the midst of what has mostly been a rough November, particularly for growth investors. Maybe today’s run-up will spark a turnaround. In case there are more wild gyrations ahead, however, today we add a low-beta, way-undervalued utility stock that I recommended to my Cabot Value Investor audience earlier this month. We could use a couple more defensive positions as the market has become more risk-off, and this stock certainly qualifies.

Details inside.

It was another rocky week for the market as the tone was set by a rotation out of richly valued tech names, worries over whether the Federal Reserve would stay on hold rather than cut interest rates, and the big story was ongoing concerns about the sustainability of the AI-driven rally. By week’s end the S&P 500 and Dow had lost 2%, while the Nasdaq fell 3.2%.

It was another rocky week for the market as the tone was set by a rotation out of richly valued tech names, worries over whether the Federal Reserve would stay on hold rather than cut interest rates, and the big story was ongoing concerns about the sustainability of the AI-driven rally. By week’s end the S&P 500 and Dow had lost 2%, while the Nasdaq fell 3.2%.

*Note: Your next issue of Cabot Explorer will arrive next Wednesday, November 26 due to the market holiday next Thursday, November 27 in observance of Thanksgiving Day.

Nvidia (NVDA) sales in the October quarter hit a record $57 billion as demand for the company’s advanced Blackwell AI data center chips continued to surge, up 62% from the year-earlier quarter and beating consensus estimates. This should keep AI momentum moving forward.

By coincidence, Saudi Arabia’s Crown Prince Mohammed bin Salman’s (MBS) high level visit to Washington this week led to the Commerce Department approving sales of substantial advanced chips to Saudia Arabia as well as a slew of related deals. My question is whether these deals are investing in Saudi’s economic transformation rather than in American jobs, technology, and growth.

The market continues to be on edge but having lightened up over the last two and a half months we’re in a decent position to add some exposure today.

This month’s issue offers fresh opportunities in the red-hot pharma space, as well as two little-known mid-cap industrial stories, one in radiation protection and the other in the oil and gas market. Wrapping things up is an introduction to what’s arguably the best play on utility-scale solar.

Enjoy!

Before we dive into this week’s idea we need to move on from our Applied Digital (APLD) covered call as the stock has come under intense selling pressure as the AI story has weakened.

Value stocks have outperformed the market of late, with the Vanguard Value Index Fund (VTV) up 2.9% in the last month vs. a 2.3% return in the S&P 500. Granted, that’s minuscule outperformance, but it’s a sign that investors are starting to look for value with the major indexes at or near all-time highs for the last couple months.

The market is at another new high and looking good. Anticipated Fed rate cuts and a revitalized artificial intelligence trade are driving stocks higher.

It’s Fed Day! And a rate cut is expected. That’s even better than Prince Spaghetti night to Wall Streeters. More than 90% of traders are expecting the first fed funds rate cut in 2025 to be 0.25%. Hopes for a 0.50% cut likely went out the window with the higher-than-expected August CPI number.

Stocks made another new high this week as investors expect a resumption of Fed rate cuts on Wednesday.

The Fed Chairman indicated that the fed funds rate will be cut at the September meeting during his Jackson Hole comments last month. Wall Street traders are pricing in a 90%-plus probability of a 0.25% cut on Wednesday. And consensus expectations are for two more such cuts before the end of this year.

The ultimate “fear gauge” isn’t the CBOE Volatility Index (VIX), as financial market pundits often insist. My contention is that it’s actually gold, which arguably is the most historically reliable barometer of how worried the average investor is over various economic, geopolitical and market-related developments.

WHAT TO DO NOW: The top-down, market-wide evidence remains in good shape, and encouragingly, growth stocks have revved up decently over the past week, though the action remains heavily concentrated in AI infrastructure-type names. There are still lots of crosscurrents and many names are hitting the occasional pothole, though, so picking your stocks and spots remains vital. In the Model Portfolio we’re making one new buy—a half-sized stake in Alnylam Pharmaceuticals (ALNY)—while placing MP Materials (MP) on Hold. We could have some other moves in the next few days (including averaging up on names in the portfolio), but tonight we’ll buy ALNY and go from there. Our cash position will be around 43%.

With jobs numbers (and revisions) looking pretty iffy and inflation numbers looking as expected (CPI, today), if not slightly better (PPI, yesterday), the chances of the Fed cutting rates next Wednesday are essentially a lock.

In fact, the only reason the probability of a 25bps cut is only 89% is because the chance of a 50bps cut is 11%!

The market likes this news very much. And so do small caps.

This is, almost certainly, our last update before the Fed starts slashing interest rates for the first time this year. According to the CME Group’s FedWatch Tool, there is now a 100% chance Jerome Powell and company will cut rates by some amount on September 17; 90% think it will be by 25 basis points, another 10% think it will be by 50 basis points, much like last September.

The waiting game continues. President Donald Trump teased cannabis rescheduling in an August 11 press briefing, suggesting it would happen in a few weeks.

A month has passed, but no joy yet for cannabis investors.

While it would make more sense to reschedule closer to the 2026 mid-term elections for greater political impact, media reports once again recently cited Washington, D.C., insiders who say rescheduling will happen soon.

The market is enduring the post-summer market well, so far. The expected Fed rate cut is pushing stocks higher.

There are few things Wall Street loves more than rate cuts. And there is one almost surely on the way. Traders are assigning better than 90% probability to a cut. But speculation is growing as an increasing number of analysts expect a 0.50% cut, instead of the usual 0.25%.

It has been called “Beijing’s missile fashion week” by news outlets, and it commanded a fair share of this week’s headlines. It’s also a reminder to investors why the defense sector is still in a leadership position from a relative strength standpoint, driven by ongoing military conflicts in Eastern Europe and the Middle East.

Yesterday, Alphabet (GOOG) shares were up 8% after it avoided harsh antitrust penalties keeping its browser and partnership with Apple (APPL). Alibaba (BABA) shares were up 9.9% this week as quarterly cloud growth was up 26% year-over-year and profits exceeded expectations.

Uncertainty and a weak dollar are two reasons gold and silver are doing so well. The pressure on the Federal Reserve, political volatility, and voracious central bank buying from China and other countries are also factors.

The post-Labor Day market is here. And it’s starting off ugly.

The sobered-up, post-summer investor is notoriously cranky. That’s why September is historically the worst month. Combine that fact with a market that is within a whisker of the high with plenty of uncertainty swirling around, and you have a recipe for trouble.

The broad market indices are up nicely today on news of significant de-escalation of U.S.-China trade tensions following weekend talks in Switzerland.

Earnings Roundup

Natural Grocers (NGVC) should have a decent day (+20% in early hours trading) after Q2 earnings beat expectations. Revenue grew 9.0% to $335.8 million (a $6.1 million beat) while GAAP EPS of $0.56 grew by 60%. Daily average comparable store sales grew by 8.9%. This was a very strong quarter.

Shares of Artivion (AORT) are up over 12% today after the company beat expectations in the first quarter. Revenue grew 1.6% (Q1 of last year was a monster quarter so a tough comparison) to $99 million versus expectations of $94.8 million while adjusted EPS of $0.06 beat expectations by $0.02.

MSFT, FRSH, SFM Earnings Roundup

Enovix (ENVX) reported Q1 results yesterday after the close that met revenue expectations with $5.1 million. Operating expenses rose in the quarter and will continue to do so into Q2 to support the ramp up to mass production and to prepare for higher production capacity at the newly acquired South Korean battery manufacturing plant.

GE Vernova (GEV) and Sportradar (SRAD) Updates

This has been a difficult month with high levels of uncertainty.

The concurrent declines in the U.S. dollar and S&P 500 are part of a trend that has swept markets since the broad and steep tariffs were announced.

Sell Teladoc Health (TDOC)

Today, a whopping eight Profit Booster positions will expire. Most are “slam-dunk,” full-profit trades, while others will go down to the wire.

The big takeaway, before we dive in, is we are going to let the situation play itself out, and come Monday/Tuesday of next week we will revisit our profits, as well as how we will manage the remaining positions.

While there have been some crazy moves in the market this week, it’s somewhat encouraging that, as of 12:00 PM ET, the broad market isn’t off that much compared to Friday’s close.

It’s been encouraging to see the market stabilize over the last two days (though yesterday was a crazy session).

A few Cabot Options Trader subscribers have asked me about ways to protect gains in their portfolios, so I thought I would write to everyone with a couple of strategies using options to hedge your portfolio.

A subscriber recently asked me if I keep a journal of my trades. Many traders keep journals so they can look back at their trades and evaluate what they did right and what they did wrong.

Want to know how the big institutional investors use options? Here is an example of how one trader spent $132 million on three technology stocks.

Options trading has its own vernacular. To know how to do it, you need to know what every options term means. Here are some of the basics.

Our Cabot Top Ten Trader’s market timing system consists of two parts—one based on the action of three select, growth-oriented market indexes, and the other based on the action of the fast-moving stocks Cabot Top Ten features.